Literature DB >> 10427584

Physico-chemical stability of docetaxel premix solution and docetaxel infusion solutions in PVC bags and polyolefine containers.

J Thiesen1, I Krämer.   

Abstract

We assessed the physical and chemical stability of docetaxel infusion solutions. Stability of the antineoplastic drug was determined 1.) after reconstitution of the injection concentrate and 2.) after further dilution in two commonly used vehicle-solutions, 0.9% sodium chloride and 5% dextrose, in PVC bags and polyolefine containers. Chemical stability was measured by using a stability-indicating HPLC assay with ultraviolet detection. Physical stability was determined by visual inspection. The stability tests revealed that reconstituted docetaxel solutions (= premix solutions) are physico-chemically stable (at a level > or = 95% docetaxel) for a minimum of four weeks, independent of the storage temperature (refrigerated, room temperature). Diluted infusion solutions (docetaxel concentration 0.3 mg/ml and 0.9 mg/ml), with either vehicle-solution, proved physico-chemically stable (at a level > or = 95% docetaxel) for a minimum of four weeks, when prepared in polyolefine containers and stored at room temperature. However, diluted infusion solutions exhibited limited physical stability in PVC bags, because docetaxel precipitation occurred irregularly, though not before day 5 of storage. In addition, time-dependent DEHP-teaching from PVC infusion bags by docetaxel infusion solutions must be considered.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10427584     DOI: 10.1023/a:1008644801096

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  12 in total

1.  Compatibility of docetaxel and paclitaxel in intravenous solutions with polyvinyl chloride infusion materials.

Authors:  D J Mazzo; J J Nguyen-Huu; S Pagniez; P Denis
Journal:  Am J Health Syst Pharm       Date:  1997-03-01       Impact factor: 2.637

2.  Precipitation of teniposide during infusion.

Authors: 
Journal:  Am J Hosp Pharm       Date:  1990-03

3.  Chemical and physical stability of etoposide and teniposide in commonly used infusion fluids.

Authors:  J H Beijnen; A U Beijnen-Bandhoe; A C Dubbelman; R van Gijn; W J Underberg
Journal:  J Parenter Sci Technol       Date:  1991 Mar-Apr

4.  Stability of paclitaxel in 5% dextrose injection or 0.9% sodium chloride injection at 4, 22, or 32 degrees C.

Authors:  Q Xu; L A Trissel; J F Martinez
Journal:  Am J Hosp Pharm       Date:  1994-12-15

Review 5.  Antitumor activity of docetaxel.

Authors:  J R Eckardt
Journal:  Am J Health Syst Pharm       Date:  1997-12-15       Impact factor: 2.637

Review 6.  Pharmaceutical aspects of docetaxel.

Authors:  M A Kraynak
Journal:  Am J Health Syst Pharm       Date:  1997-12-15       Impact factor: 2.637

7.  Relationships between the structure of taxol analogues and their antimitotic activity.

Authors:  F Guéritte-Voegelein; D Guénard; F Lavelle; M T Le Goff; L Mangatal; P Potier
Journal:  J Med Chem       Date:  1991-03       Impact factor: 7.446

8.  Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition.

Authors:  J F Díaz; J M Andreu
Journal:  Biochemistry       Date:  1993-03-23       Impact factor: 3.162

Review 9.  Preclinical pharmacology of docetaxel.

Authors:  M C Bissery
Journal:  Eur J Cancer       Date:  1995       Impact factor: 9.162

Review 10.  Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience.

Authors:  M C Bissery; G Nohynek; G J Sanderink; F Lavelle
Journal:  Anticancer Drugs       Date:  1995-06       Impact factor: 2.248

View more
  6 in total

1.  Leachables from saline-containing IV bags can alter therapeutic protein properties.

Authors:  Judy Y Chang; Nina J Xiao; Min Zhu; Jennifer Zhang; Ed Hoff; Stephen J Russell; Viswanatham Katta; Steven J Shire
Journal:  Pharm Res       Date:  2010-06-30       Impact factor: 4.200

Review 2.  Stability of antineoplastic agents in use for home-based intravenous chemotherapy.

Authors:  Frédéric Benizri; Brigitte Bonan; Anne-Laure Ferrio; Marie-Laure Brandely; Vincent Castagné; Nathalie Théou-Anton; Muriel Verlinde-Carvalho; Laurent Havard
Journal:  Pharm World Sci       Date:  2008-12-10

3.  Nanosomal Docetaxel Lipid Suspension: A Guide to Its Use in Cancer.

Authors:  Kate McKeage
Journal:  Clin Drug Investig       Date:  2017-04       Impact factor: 2.859

4.  High concentrated etoposide solutions, additional physical stability data in dextrose 5.

Authors:  Marine Ravey; Caroline Polo; Elise D'Huart; Jean Vigneron; Béatrice Demoré
Journal:  Eur J Hosp Pharm       Date:  2020-10-20

5.  Physical and chemical stability of Taxotere (docetaxel) one-vial (20 mg/ml) infusion solution following refrigerated storage.

Authors:  M Hart; S Acott
Journal:  Ecancermedicalscience       Date:  2010-12-15

Review 6.  How nanotechnology can enhance docetaxel therapy.

Authors:  Li Zhang; Na Zhang
Journal:  Int J Nanomedicine       Date:  2013-08-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.